Psychedelics as a Treatment for Alzheimer’s Disease Dementia Simon Andrew Vann Jones and Allison O’Kelly Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34 doi : 10.3389/fnsyn.2020.00034 Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic [...]
Lire la suiteSoignera-t-on un jour grâce au LSD et aux champignons hallucinogènes ? The Conversation, 8 octobre 2020, Mis à jour le 9 octobre 2020, https://theconversation.com/soignera-t-on-un-jour-grace-au-lsd-et-aux-champignons-hallucinogenes-127760 Auteur Vincent Verroust Chercheur associé à l’Institut des humanités en médecine (Lausanne), doctorant en histoire des sciences à l’École des hautes études en sciences sociales (Paris), centre Alexandre-Koyré (EHESS-CNRS-MNHN), Muséum national d’histoire naturelle (MNHN) Déclaration d’intérêts : Vincent Verroust est président de la Société psychédélique française. Cet article a été co-écrit avec Bertrand Lebeau Leibovici, médecin addictologue à l’hôpital Saint-Antoine (Paris) et à l’hôpital Paul Brousse (Villejuif). Partenaires Muséum National d’Histoire Naturelle apporte un financement en tant que membre adhérent [...]
Lire la suiteMystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland Samuli Kangaslampi, PhD , Aino Hausen, BA, and Tarina Rauteenmaa, BA JOURNAL OF PSYCHOACTIVE DRUGS, 2020, 1-10 Doi : 10.1080/02791072.2020.1767321 ABSTRACT Despite their acutely inebriating and sometimes unpleasant effects, some people report positive changes in life satisfaction, well-being, or mental health after taking psychedelic drugs. One explanation may be the ability of psychedelics to trigger mystical-type experiences. We examined the validity, reliability, and factor structure of a novel Finnish translation of the Revised Mystical Experiences Questionnaire (MEQ30) among 288 people retrospectively reporting on their first time using a psychedelic. We found evidence [...]
Lire la suiteAntidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Jordi Riba, Antônio W. Zuardi and Jaime E. C. Hallak Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3) 193–213 Doi : 10.1177/2045125316638008 Abstract : To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have [...]
Lire la suiteRecent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens Adam L. Halberstadt Behavioral Brain Research, 2015, 15, 277, 99–120. doi : 10.1016/j.bbr.2014.07.016 Abstract Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse [...]
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : anthropologie, sociologie, spiritualité, chamanisme, culture… Docteur Christian Sueur, GRECC, mai 2020 Substances psychédéliques, anthropologie, sociologie, culture… : pp 1 - 6 Substances psychédéliques et Chamanisme : pp 7 - 10 Psychédéliques et “spiritualité” : religion, mysticisme, enthéogènes : pp 11 - 23
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie, … Dr Christian SUEUR, GRECC, mai 2020 (nouvelle version) Substances psychédéliques : Généralités, Pharmacologie, Neurophysiologie : 1 - 17 Substances psychédéliques et «psychologie » : 18 - 20 Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, culture, chamanisme, spiritualité, religion… Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca, Bibliographie : Mescaline et Peyotl, Bibliographie : MDMA, Bibliographie : Tryptamines …
Lire la suiteDynamic coupling of whole-brain neuronal and neurotransmitter systems Morten L. Kringelbach, Josephine Cruzat, Joana Cabral, Gitte Moos Knudsen, Robin Carhart-Harris, Peter C. Whybrow Nikos K. Logothetis, and Gustavo Deco PNAS, 2020, 1-11 doi : 10.1073/pnas.1921475117 Remarkable progress has come from whole-brain models linking anatomy and function. Paradoxically, it is not clear how a neuronal dynamical system running in the fixed human anatomical connectome can give rise to the rich changes in the functional repertoire associated with human brain function, which is impossible to explain through long-term plasticity. Neuromodulation evolved to allow for such flexibility by dynamically updating the effectivity of the fixed anatomical connectivity. [...]
Lire la suiteDe la première vague à la renaissance psychédélique ATHS 2019, Biarritz, 1-4 octobre 2019 Dr Bertrand LEBEAU LEIBOVICI Les psychédéliques « classiques » A l’exception du LSD, ce sont des substances naturelles consommées par certains peuples depuis des millénaires Les psychédéliques « classiques » interagissent avec le récepteur 5HT2a : LSD psilocybine DMT (Diméthyltryptamine) mescaline Une définition plus large des psychédéliques : Les entactogènes et empathogènes: MDMA, MDA, 2-CB, 2C-T-7 etc. Les substances dissociatives antagonistes NMDA : kétamine, PCP Les substances dissociatives agonistes kappa-opioïdes : ibogaïne et Salvia Divinorum Tryptamines et phényléthylamines : Les psychédéliques sont : soit des tryptamines : LSD, psilocybine, DMT, ibogaïne, bufoténine (5-hydroxy-DMT) soit des phényléthylamines: MDMA, mescaline, MDA, 2C-B etc. La psychiatrie en [...]
Lire la suiteRethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models Claire J. Foldi, Paul Liknaitzky, Martin Williams, Brian J. Oldfield Frontiers in Neuroscience, 2020 | Volume 14 | Article 43 : 1-8 doi : 10.3389/fnins.2020.00043 Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN [...]
Lire la suite